The manufacturing facility will house both the research and development and manufacturing teams.
The facility will focus its production efforts on the company’s pipeline of biologic medicines, including gene therapies and vaccines. Glaxo hopes having the teams under one roof will speed the production of new medicines.
The expansion is part of a larger $400 million project to expand its manufacturing capabilities in vaccines and specialty medicines, according to BioPharma-Reporter.com.
Read the full article here.
More articles on pharmacy:
World Pharmacist Day promotes use of safe and effective medicines
USP delays release of updated compounding standards
Americans pay up to 67 times more for drugs than other countries
